Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: The question which is bugging me..

as a result of that knowledge, *might* think that the resulting legal fisticuffs have adversely affected the licensing effort.

Interestingly, Alliacense are contractually bound to use their best efforts in securing licenses. As PTSC have an undisputed 50% ownership of the MMP Portfolio, whatever is ongoing between Moore and TPL should have no impact as any licenses would be valid purely on PTSC's part ownership.

I'm not sure that PTSC have to announce new signings because licensing is now part of their established business. Might it be simply keeping shareholders informed?

Throw in the Californian stay and it could be any number of reasons.

As always, shareholders are left awaiting the decisions of others.

.

.

Be well

Share
New Message
Please login to post a reply